Uncategorized
Schrödinger Halts SGR-2921 Leukaemia Programme After Two Deaths
Schrödinger; SGR-2921; leukaemia; acute myeloid leukaemia (AML); myelodysplastic syndromes (MDS); CDC7 inhibitor; clinical trial halt; patient deaths; drug safety
NIH and HHS Cancel Major mRNA Vaccine Research Funding, Citing Lack of Public Trust
NIH; mRNA vaccine; public trust; research funding; BARDA; COVID-19; vaccine hesitancy; RFK Jr.; Jay Bhattacharya; grant cancellation
Hatteras Raises $200M for Two New Funds Following HistoSonics Exit Success
Hatteras Venture Partners; $200M; venture capital; life sciences; early-stage startups; biotech; medtech; HistoSonics exit; fundraising; Hatteras Venture Fund VII; Hatteras Opportunity Fund I
Response Pharma: RDX-002 Limits Weight Regain After GLP-1 Therapy – Positive Phase II Results Announced
Response Pharmaceuticals; RDX-002; GLP-1 discontinuation; weight regain; obesity; Phase II clinical trial; postprandial triglycerides; cardiometabolic health; iMTP inhibitor
Merck Begins Layoffs in New Jersey as Part of $3 Billion Cost-Cutting Plan
Merck & Co.; New Jersey; layoffs; pharma industry; cost-cutting; Keytruda; restructuring; WARN notice
Insmed Secures FDA Approval for First DPP1 Inhibitor in Lung Disease
Insmed; FDA approval; DPP1 inhibitor; Brensocatib; Brinsupri; bronchiectasis; lung disease
Eli Lilly Vows Vigorous Defense as Texas Sues Over Alleged Drug Kickbacks
Eli Lilly; Texas Attorney General; kickback scheme; drug prescriptions; Mounjaro; Zepbound; GLP-1 drugs; Medicaid fraud; Free Nurse Program; Support Services Program; Ken Paxton; pharmaceutical litigation
Fierce Biotech Layoff Tracker 2025: Abata Folds; Generation Lays Off 90% of Staff
biotech layoffs; Abata; Generation; Fierce Biotech Layoff Tracker; 2025; company closure; staff reduction
Uncertainty Clouds Finances for Payers and Health Systems in Q2 2025
Q2 2025; healthcare financial performance; payers; health systems; uncertainty; Medicaid; Medicare; admissions; policy changes; federal budget; consumer confidence
AbbVie Invests $195 Million in New North Chicago API Manufacturing Site
AbbVie; North Chicago; API manufacturing; $195 million investment; facility expansion; pharmaceutical manufacturing; Illinois; domestic production